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Abstract
Airway epithelial cells are the first line of defense against viral infections and are instrumental in coordinating the
inflammatory response. In this study, we demonstrate the synergistic stimulation of CXCL10 mRNA and protein, a key
chemokine responsible for the early immune response to viral infection, following treatment of airway epithelial cells with
IFN c and influenza virus. The synergism also occurred when the cells were treated with IFN c and a viral replication
mimicker (dsRNA) both in vitro and in vivo. Despite the requirement of type I interferon (IFNAR) signaling in dsRNA-induced
CXCL10, the synergism was independent of the IFNAR pathway since it wasn’t affected by the addition of a neutralizing
IFNAR antibody or the complete lack of IFNAR expression. Furthermore, the same synergistic effect was also observed when
a CXCL10 promoter reporter was examined. Although the responsive promoter region contains both ISRE and NFkB sites,
western blot analysis indicated that the combined treatment of IFN c and dsRNA significantly augmented NFkB but not
STAT1 activation as compared to the single treatment. Therefore, we conclude that IFN c and dsRNA act in concert to
potentiate CXCL10 expression in airway epithelial cells via an NFkB-dependent but IFNAR-STAT independent pathway and it
is at least partly regulated at the transcriptional level.
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Introduction
Influenza pneumonia remains a major cause of morbidity and
mortality worldwide. Airway epithelial cells are the first line of
defense against viral infections in the lung and are instrumental in
coordinating the early inflammation leading to an adaptive
immune response. CXCL10 (IFN gamma inducible 10 kDa
protein, IP10) is a non-ELR CXC chemokine with potent
biological effects including monocyte stimulation, natural killer
and activated T cell migration, modulation of adhesion molecule
expression, inhibition of angiogenesis [1] as well as antimicrobial
effects at high concentrations [2].
The role of CXCL10 in viral pneumonia has not been
thoroughly characterized but evidence suggests it is important
for the migration of NK cells, macrophages, T cells, neutrophils
and plasmacytoid dendritic cells into the lung [3,4]. In a mouse
model of RSV infection, antibody-mediated neutralization of
CXCL10 resulted in a significant increase in disease symptoms
including impaired viral clearance, reduced pulmonary dendritic
cell numbers and maturation and a reduction in viral specific
CD8(+) T cells [5].
Synergistic up-regulation of CXCL10 has been described in vitro
in several cell types and in response to different pro-inflammatory
molecules but always in conjunction with IFN c. TNFa and IFN c
induce synergistic levels of CXCL10 in a human endothelial cell
line HMEC-1 via an ERK dependent pathway [6], IL-1b and IFN
c in human intestinal epithelial cell lines [7], PDGF and IFN c in
blood derived macrophages [8], TNFa and IFN c in primary
human airway smooth muscle cells and gastric epithelial cells
[9,10], prolactin and IFN c [11] as well as substance P and IFN c
in human keratinocytes [12] and hyaluronan fragments with IFN
c in mouse macrophages [13]. Interestingly, synergistic induction
of CXCL10 has been described with IFN c in conjunction with
HIV-1 in human astrocytes and macrophages and thought to play
a role in HIV induced encephalopathy [14,15]. This marked
variety of pro-inflammatory molecules that elicit a synergistic
response of CXCL10 in a wide variety of cell types is indicative of
a highly conserved and likely biologically important cellular
response. However, synergistic induction of CXCL10 in response
to influenza and IFN c in airway epithelial cells has not been
previously reported.
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In this study, we demonstrate synergistic induction of CXCL10
in well differentiated primary human bronchial epithelial (HBE)
cells following influenza virus infection and the treatment with IFN
c. We further demonstrate that this synergy was mediated by the
interaction between dsRNA (an intermediate of viral replication)
and IFN c in vitro and in vivo. In the follow-up mechanistic study,
this synergism was found to be transcriptionally regulated as
demonstrated by a chimeric promoter reporter gene assay. In
addition, it was not dependent of the IFNAR pathway as neither
the neutralizing antibody to IFNAR nor the IFNAR deficiency
affected the synergism. Finally, NFkB, but not STAT1, appeared
to mediate this synergism.
Materials and Methods
Culture and treatments of primary human bronchial
epithelial (HBE) cells
Human bronchial tissues were purchased from the commercial
source (National Disease Research Interchange, Philadelphia, PA)
as described before [16,17]. No tissues from patients diagnosed
with lung-related diseases were used. All those lungs were either
autopsy leftovers or were rejected for transplant. They were sent to
us with arbitrary numerical code. No identity link to the actual
patient can be identified. Protease-dissociated HBE cells were
plated on TranswellH chambers (Corning) and were maintained in
immersed culture conditions until they reached confluence when
they were transferred to an air-liquid interface (ALI) culture
condition [16,17]. At air-liquid interface, the cells were maintained
in a Ham’s F12/DMEM (1:1) with the addition of transferrin
(5 mg/ml), insulin (5 mg/ml), cholera toxin (10 ng/ml), epidermal
growth factor (10 ng/ml), dexamethasone (0.1 mM), bovine
hypothalamus extract (15 mg/ml), BSA (0.5 mg/ml) and all-trans-
retinoic acid (30 nM). Cells were maintained at ALI for 7 days and
were placed in basal media devoid of the additives, with the
exception of retinoic acid, overnight prior to the experiments.
Recombinant IFN c was purchased from R&D Systems and
synthetic double stranded (ds) RNA (i.e. poly I:C) from EMD
Biosciences. IFN c was used at 50 ng/ml and poly I:C at 25 mg/
ml. A neutralizing antibody to IFNAR was obtained from US
Biologics and used at 2.5 mg/ml [18]. Both IkB kinase and JAK
inhibitors were purchased from EMD Biosciences and used at
5 mM. For influenza infection, cells were infected with the
influenza virus strain MEM at 1200 HAU.
Mice
For in vivo study, BALB/c mice were purchased from Charles
Rivers Laboratories and used at 6–8 weeks of age for intra-
tracheal instillations. For primary airway epithelial cell cultures,
IFNAR null mice were a kind gift from Dr. Nicole Baumgarth
(UCD) and the wild-type controls mice were C57BL/6J. Mice
were used at 8–10 weeks of age. All protocols described were
approved by the University of California, Davis and University of
Arizona, which were responsible for the proper care and use of
experimental animals.
Culture and treatments of primary mouse tracheal
epithelial (MTE) cells
The protocol was performed as described previously [19].
Briefly, at the time of necropsy, the chest and cervical region were
exposed. A small puncture was placed in the proximal trachea to
allow cannulation with sterile 0.86 mm polyethylene tubing
(Intramedic Clay Adams) which was secured in place with a 3.0
silk suture. A loose suture was placed at the distal end of the
trachea just proximal to the carina. The trachea was dissected free
and immediately placed in DMEM at 4uC. And each trachea
gently inflated with 0.2% protease through the tracheal cannula
after tightening the distal suture. Dissociated epithelial cells were
gently harvested by injecting 5 milliliters of cell culture media
through the trachea. MTE cells from all tracheas were pooled and
re-suspended in cell culture media prior to plating on Transwell
chambers (Corning) coated with Purcol (Advanced Biomatrix).
MTE cells were maintained in submerged conditions until
confluent at which time they were kept in air-liquid interface
conditions for one week in the presence of 100 nM retinoic acid.
For the experiments, MTE cells were treated with 50 ng
recombinant murine IFN c (R and D systems) and/or 25 mg
dsRNA for 24 hours.
Mouse model of synergism
The protocol was performed as described previously [20,21].
Briefly, BALB/c mice were anesthetized with isoflorane. In dorsal
recumbancy, the tongue was gently pulled out, and a pipette tip
was gently inserted into their laryngeal region through the oral
cavity. 2 mg of dsRNA and/or 5 mg of recombinant murine IFN c
in 50 ml of LPS free PBS was deposited and breathed in. LPS free
PBS was used as the control. Mice were kept in an upright position
until recovery from anesthesia. Twenty four hours later, mice were
euthanized, and lungs were lavaged with 1 ml PBS. All lungs were
flash frozen in liquid nitrogen for subsequent RNA isolation.
RNA isolation and real-time RT-PCR
Total RNA was extracted with TRIzol reagent (Invitrogen)
and cDNA was generated from an equal amount of RNA (1 mg
per reaction) by Moloney’s murine leukemia virus-reverse
transcriptase (Applied Biosystems) using random hexamers (In-
vitrogen). SYBR Green Master Mix (Roche Applied Science) and
the ABI7900HT Detection System (Applied Biosystems) were used
following the manufacturer’s protocol for real-time PCR analysis.
The relative mRNA amount of each sample was calculated based
on its threshold cycle, Ct, in comparison to the Ct of the
housekeeping gene, beta actin or glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). The results are presented as 22(Ct
CXCL10– Ct of housekeeping gene) as fold induction over the control
condition. The purity of the amplified product was determined as
a single peak of the dissociation curve. Throughout the study,
there was no observable fluctuation in the Ct values of the
housekeeping genes from different treatment conditions. Primers
to human and murine CXCL10 were purchased from SA
Biosciences. The primer sequences for human beta actin are as
follows: forward: TGTGTCCGTCGTGGATCTGA and reverse:
CCTGCTTCACCACCTTCTTGAT. The primer sequences for
murine GAPDH are as follows: forward: TCCTCCACCTTT-
GACGCTG and reverse: ACCACCCTGTTGCTGTAGCC.
CXCL10 ELISA
In preparation for collecting conditioned media from primary
human airway epithelial cells, the cells were washed twice with
sterile PBS. Fresh media containing IFN c and/or poly I:C was
placed basally with 100 ml of media placed apically. Following a
24 hour incubation, the media was harvested, centrifuged to
remove any cellular debris and stored at 280uC. Bronchoalveolar
lavage fluid was used for the murine CXCL10 ELISA. Commer-
cially available ELISA kits were used according to the manufac-
turer’s directions (R&D Systems). Results were normalized to the
amount of conditioned media or lavage fluid and expressed as ng/
ml or pg/ml.
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Luciferase assay
The construct contains 735 bp upstream of the transcription
start site of CXCL10 was cloned into PGL3 luciferase reporter
vector (promega). The construct was confirmed by DNA
sequencing. Early differentiated HBE cells (7 days) were trans-
fected with CXCL10 promoter-luciferase construct and pRL-TK
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s specifications. pRL-TK was used as the internal control for
normalizing transfection efficiency. The empty vector, pGL3 basic
was used as a negative control. In brief, cells were plated onto 12
well plates at 80–90% confluency. The next day, cells were washed
twice with Opti-MEM (Invitrogen) before transfection. The cells
were incubated at 37uC with the mixture of DNA constructs and
Lipofectamine 2000 in Opti-MEM for 5–6 hours at which time
cell culture media was also added to the cells. Transfected cultures
were treated with 50 ng/ml IFN c and/or 25 mg poly I:C for 24
hours. A dual luciferase reporter assay kit (Promega) was used
following the manufacturer’s protocol. For each transfection, the
relative firefly luciferase activity was normalized to the renilla
luciferase activity.
Neutralization of IFNAR
2.5 mg/ml of a mouse monoclonal antibody to chain 2 of the
human alpha, beta, omega interferon receptor (IFNAR) was added
to culture media of cells for 1 hour prior to the start of the
experiment. This antibody has previously been documented to
neutralize the extracellular domain of the human type I interferon
receptor with high affinity at the dose used in this study [18]. IFN
c and/or poly I:C were added to the culture media following the
pre-incubation period and with the IFNRA antibody still present.
Mouse IgG was used as the control. Following a 24 hour
incubation, RNA isolation and qPCR were performed as
previously described.
Statistical analysis
Data are expressed as mean 6 SE. Experiments were
conducted in triplicate with at least three independent cultures.
Group differences were calculated using an Analysis of Variance
(ANOVA) followed by a Bonferroni multiple comparison test.
Differences were considered significant for p values less than 0.05.
Results
Synergistic stimulation of CXCL10 mRNA following
influenza virus infection and IFN c treatment in HBE cells
As shown in Fig. 1A, well differentiated HBE cells demonstrated
significant synergistic induction of CXCL10 mRNA following
infection with the MEM influenza virus and treatment with IFN c.
CXCL10 induction was also significantly elevated following the
combined treatment of MEM and IFN c treatment as compared
to the treatment with IFN c alone. Consistently, potentiation of
CXCL10 protein production by the combined treatments was
detected in the cell culture supernatant from HBE cells (Fig. 1B).
Apical release of CXCL10 was enhanced in all treatment
conditions with more pronounced levels detected in the combined
MEM infection and IFN c treatment (Fig. 1B). Interestingly,
significant levels of CXCL10 were also released basally except that
they were much lower than the apical secretion. These results
demonstrate that influenza virus in combination with IFN c
synergistically induce CXCL10 mRNA and protein production
from primary human airway epithelial cells.
Synergistic stimulation of CXCL10 mRNA and protein by
IFN c and dsRNA in HBE cells
Because viral replication and its intermediate-double stranded
(ds) RNA have been shown to mediate many influenza induced
phenotypes. We then examined the possibility if dsRNA could
synergize with IFN c in the induction of CXCL10. As shown in
Fig. 2A, HBE cells demonstrated synergistic induction of CXCL10
mRNA in a time dependent manner starting as early as 3 hours
after treatment. Treatment with IFN c and dsRNA resulted in
significant synergistic induction of CXCL10 mRNA levels at all
the time points. Combined treatment for 24 hours resulted in an
over 8000 fold induction of CXCL10 mRNA. Consistently, Fig. 2B
demonstrates potentiation of CXCL10 protein in cell culture
supernatant from HBE cells treated for 24 hours. Apical release of
CXCL10 was enhanced in all treatment conditions with more
pronounced levels detected in the combined IFN c and dsRNA
treatment. Significant levels of CXCL10 were also released
basally, although the levels were much lower than the apical
secretions. These results suggest that the synergy between
influenza infection and IFN c treatment may be caused by the
interaction between dsRNA- and IFN c-mediated signaling
pathways.
Synergistic stimulation of CXCL10 mRNA and protein
in vivo
To determine whether IFN c and dsRNA synergistically induce
CXCL10 in vivo, we performed intra-tracheal delivery of IFN c
and dsRNA in BALB/c mice and examined CXCL10 mRNA and
protein levels. As shown in Fig. 3A, dsRNA alone induced a
significant increase in CXCL10 mRNA, and IFN c and dsRNA
treatment together synergistically induced CXCL10 mRNA 54
fold in mouse lung. Likewise, Fig. 3B demonstrates a significant
induction of CXCL10 protein in bronchoalveolar lavage fluid
after treatment with dsRNA and synergistic induction following
IFN c and dsRNA treatment. These results demonstrate
synergistic induction of CXCL10 mRNA and protein in vivo
following IFN c and dsRNA treatment.
Synergistic stimulation of CXCL10 gene by IFN c and
dsRNA is independent of the type I interferon pathway
Because dsRNA is known to induce the type I interferon
pathway, we investigated the involvement of this pathway by using
a neutralizing antibody to human IFNAR. Fig. 4A demonstrates
that the IFNAR neutralizing antibody did not affect synergistic
induction of CXCL10 mRNA in HBE cells, although it did repress
dsRNA-induced CXCL10. To confirm this result, we isolated
MTE cells from IFNAR null mice, which were completely lack of
IFNAR expression. Fig. 4B demonstrates that the lack of IFNAR
did not affect the synergistic induction of CXCL10. Interestingly,
induction of CXCL10 by dsRNA alone was significantly impaired
in the MTE cells from IFNAR null mice as compared to the cells
from wild-type mice. Taken together, these results demonstrate
that synergistic induction of CXCL10 mRNA was independent of
the type I interferon receptor in both human and mouse airway
epithelial cells. In contrast, dsRNA-induced CXCL10 appeared to
depend on the type I interferon receptor, suggesting that the
synergy may be mediated via a different pathway.
The synergy between IFN c and dsRNA on CXCL10
promoter
Because of the rapid elevation of CXCL10 by IFN c and/or
dsRNA (Fig. 2A), we tested the possibility if this synergy occurred at
transcriptional level by transient transfection of the HBE cells with
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a CXCL10 promoter/luciferase chimeric construct containing
735 bp of the upstream regulatory region of CXCL10. Fig. 5
demonstrates the combined treatment of IFN c and dsRNA
significantly increased the luciferase reporter gene activity as
compared with the treatment of IFN c or dsRNA alone. These
results support that the synergism occurred at least partially
through a direct transcriptional mechanism and the proximal
735 bp region of the CXCL10 promoter was critical for the
induction.
Figure 1. CXCL10 mRNA and protein induction in HBE cells with influenza virus infection. Well differentiated primary HBE cells were
treated with 50 ng/ml IFN c and/or 1200 HAU MEM influenza virus for 24 hours. A) RNA was isolated followed by qPCR analysis. B) Culture media from
either apical or basal compartment were collected and analyzed by ELISA assay. Black bars: IFN c only, grey bars: MEM only, hatched bars: IFN c+MEM.
Triplicate wells were used for each experiment and experiments were repeated at least three times using cultures derived from different donors. *:
p,0.05 compared to the control. #: p,0.05 compared to either IFN c treatment or MEM infection alone.
doi:10.1371/journal.pone.0100978.g001
Figure 2. Time-dependent CXCL10 mRNA and protein induction in HBE cells with dsRNA treatment. Well differentiated primary HBE
cells were treated with 50 ng/ml IFN c and/or 25 mg/ml dsRNA. RNA was collected at 3, 12 or 24 hours and analyzed by qPCR. Culture media from
either apical or basal compartment were collected at 24 hours and analyzed by ELISA assay. Black bars: IFN c only, grey bars: dsRNA only, hatched
bars: IFN c + dsRNA. Triplicate wells were used for each experiment and experiments were repeated at least three times using cultures derived from
different donors. *: p,0.05 compared to the control. #: p,0.05 compared to either IFN c or dsRNA treatment alone.
doi:10.1371/journal.pone.0100978.g002
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Synergistic stimulation of CXCL10 was mediated by NFkB
pathway
Because both NFkB and ISRE sites were present in this cloned
CXCL10 promoter region, we further tested NFkB and STAT
pathways in this synergism as both pathways have been shown to
be responsible for CXCL10 gene expression. Indeed, the specific
inhibitor targeting the kinase either upstream of NFkB (IkB
kinase) or STAT1 (JAK) significantly blocked CXCL10 induction
by IFN c, by dsRNA, or by the combined treatment (Fig. 6A),
which confirms the indispensable role of both pathways in
Figure 3. CXCL10 mRNA and protein induction in BALB/c lungs. BALB/c mice were treated with 5 mg/ml IFN c and/or 2 mg dsRNA (dsR).
Twenty four hours later, bronchoalveolar lavage fluid and trachea and lungs were harvested. N= 3 per condition. Values are presented as the mean6
SE. A) Total RNA was isolated from the trachea and lungs followed by qPCR. B) CXCL10 protein was assayed in BAL fluid using an ELISA. Samples were
normalized to BAL returned volume. *: p,0.05 compared to the control. #: p,0.05 compared to either IFN c or dsRNA treatment alone.
doi:10.1371/journal.pone.0100978.g003
Figure 4. The synergism between IFN c and dsRNA(dsR) was independent of IFNAR. A) HBE cells were treated with 2.5 mg/ml of either an
isotype control antibody (black bar) or a monoclonal neutralizing antibody IFNAR (Grey bar) for one hour prior to the addition of 50 ng/ml IFN c and/
or 25 mg/ml dsRNA for 24 hours. RNA was isolated followed by qPCR. NS: not significant. $: p,0.05. isotype control antibody vs. IFNAR. B) Primary
MTE cells isolated from either wild-type (black bar) or IFNAR deficient (grey bar) mice were grown in vitro and treated with 50 ng/ml IFN c and/or
25 mg/ml dsRNA for 24 hours. RNA was isolated followed by qPCR. NS: not significant. $: p,0.05. wild-type vs. IFNAR deficient. Triplicate wells were
used for each experiment and the experiment was repeated at least three times.
doi:10.1371/journal.pone.0100978.g004
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regulating CXCL1 expression. When the signaling pathway was
further examined, the treatment of IFN c or dsRNA alone was
found to induce robust degradation of IkB, a surrogate of the
activation of NFkB pathway which is initiated by the reaction
catalyzed by IkB kinase. And the combined treatment resulted in
much greater IkB degradation as compared to the single treatment
(Fig. 6B). In contrast, despite the activation of STAT1A and
STAT1B by these treatments, no synergism was observed (Fig. 6B).
Therefore, the synergism of IFN c and dsRNA on CXCL10
expression was mediated by NFkB pathway.
Discussion
Airway epithelial lining is the first defense against respiratory
viral infection. In this study, we seek to understand the modulation
of an important chemokine-CXCL10 by the combined effects of
IFN c and viral infection. This is the first report documenting the
observation and mechanism underlying the synergism between
IFN c and viral infection (or dsRNA treatment) in airway
epithelial cells. IFN c is a type II interferon and oftentimes
elevated in the context of viral infection. It is generally accepted
that direct innate antiviral defense is mediated by type I IFN.
Indeed, we and others have shown that dsRNA (or virus)-induced
epithelial derived type I IFN plays critical role in the airway
antiviral defense [16,21,22]. In the present study, we demonstrate
the synergy between dsRNA- and IFN c-induced signaling in the
regulation of CXCL10. Interestingly, although dsRNA-induced
CXCL10 depended on type I IFN pathway, the synergy between
dsRNA and IFN c was completely independent of it in both
human and mouse epithelial cells. This lack of dependence was
not due to the remaining residue of the IFNAR functionality in the
antibody neutralization assay, because the epithelial cells from
IFNAR deficient mice used in the Fig. 4A still preserved the
synergistic response despite the loss of entire IFNAR expression.
Thus, in the presence of IFN c, dsRNA (or virus)-induced
signaling is very likely to be altered, which emphasizes the
importance of studying the pathway crosstalk as demonstrated in
the present study.
Previous studies have demonstrated that IFN c in conjunction
with different pro-inflammatory molecules leads to a synergistic
and dramatic induction of CXCL10 in a variety of cell types
including keratinocytes, macrophages, endothelial cells and
smooth muscle cells [6,8,9,12]. Several of these studies have
demonstrated that the transcription factor, NF-kB, is involved in
CXCL10 induction in a variety of systems [7–9]. In contrast, very
few studies have demonstrated that CXCL10 induction is
Figure 5. CXCL10 promoter constructs and luciferase assay in HBE cells. CXCL10 promoter-reporter gene activity in response to 50 ng/ml
IFN c and/or 25 mg/ml dsRNA (dsR) for 24 hours. Triplicate wells were used for each experiment and experiments were repeated at least three times.
Values are expressed as the mean 6 SE. *: p,0.05 compared to the control. #: p,0.05 compared to either IFN c or dsRNA treatmen alone.
doi:10.1371/journal.pone.0100978.g005
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dependent on an ISRE site in the promoter region. Kanda and co-
workers found substance P and IFN c induced synergism of
CXCL10 in human keratinocytes was dependent on an ISRE site
and two NF-kB sites in the CXCL10 promoter located 2210 to 2
221 of the transcription start site [12]. In addition, Majumder and
co-workers found evidence that IFN c and TNF a act in synergy
via p48 complexes with STAT-1a binding to this same ISRE site
in the CXCL10 promoter of human fibrosarcoma lines [23].
Evidence that similar synergism occurs at the transcriptional level
in mouse cells has been demonstrated in a small number of in vitro
studies [13,24]. Using the murine fibroblast NIH 3T3 cell line,
Ohmoir and co-workers established that an ISRE site and one of
two NF-kB sites in a 243 bp fragment flanking the transcription
start site of the murine CXCL10 gene were critical for IFN c and
TNF a induced synergy [24]. Our study has further extended
these studies to the airway epithelial system in the context of viral
infection, and the results apparently support the importance of
NFkB.
Figure 6. NFkB-dependent signaling is responsible for the synergism between IFN c and dsRNA (dsR). A) Well differentiated primary
HBE cells were treated with 50 ng/ml IFN c and/or 25 mg/ml dsRNA for 24 hours in the presence or absence of IkB kinase or JAK inhibitor. RNA was
isolated followed by qPCR. Solvent Control: black bar; IkB kinase inhibitor: grey bar; JAK inhibitor: light grey bar. $: p,0.05. Inhibitor treatment vs.
solvent control. B) Cells were treated with 50 ng/ml IFN c and/or 25 mg/ml dsRNA for 3 hours. Cellular protein was collected and analyzed by western
blot analysis. Actin was used as a loading control. pSTAT1: phosphorylated STAT1. This is the representative image from three replicates.
doi:10.1371/journal.pone.0100978.g006
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The present study demonstrates the significant contribution of
CXCL10 from epithelial cells, which is consistent with the
emerging role of active defense by these cells in the respiratory
viral infection. CXCL10 secretion by HBE cells appeared to be
polarized. The treatment with IFN c, dsRNA and combined
treatments resulted in a progressively enhanced secretion of
CXCL10 mainly from apical surface. In contrast, the basal
secretions of CXCL10 protein in these cultures were much less.
The gradient between the apical and basal compartments may
have important implications in vivo leading to enhanced emigra-
tion of CXCR3 positive effector cells (primarily CD8+ T cells) to
the airway epithelial microenvironment.
Although dsRNA has been used extensively as a synthetic
dsRNA to model viral infections, its stabilized derivatives are also
being investigated for clinical use as an immunomodulatory agent
for use as vaccine adjuvants in anti-viral treatment and cancer
therapies [25–28]. While dsRNA was used in this study to simulate
a viral infection, it is important to note that it, in and of itself, can
also be involved in synergistic induction of CXCL10 in airway
epithelial cells. This fact could be an important consideration in
the treatment of patients with pre-existing diseases in which IFN c
is part of the pathogenesis such as viral infections.
In summary, we demonstrate IFN c and the influenza virus
synergistically induce CXCL10 in human airway epithelial cells.
This synergism is likely to be mediated by dsRNA-induced
signaling both in vitro and in vivo, which is independent of the type I
interferon receptor pathway. Furthermore, we demonstrate the
735 bp proximal region of the CXCL10 promoter plays a critical
role in regulating this synergistic induction. This region of the
CXCL10 promoter contains punitive ISRE and NFkB transcrip-
tion factor binding sites. Therefore, further study has been carried
out to demonstrate the involvement of NFkB, but not STAT1, in
this synergism. This capacity for airway epithelial cells to markedly
up-regulate CXCL10 likely has important consequences for CD8+
T cell and NK cell migration to the airway epithelial microen-
vironment following influenza virus infection.
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